Author(s): Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M,
Abstract Share this page
Abstract BACKGROUND: Despite increasing public health concerns regarding obesity, few safe and effective drug treatments are available. Combination treatment with sustained-release naltrexone and bupropion was developed to produce complementary actions in CNS pathways regulating bodyweight. The Contrave Obesity Research I (COR-I) study assessed the effect of such treatment on bodyweight in overweight and obese participants. METHODS: Men and women aged 18-65 years who had a body-mass index (BMI) of 30-45 kg/m(2) and uncomplicated obesity or BMI 27-45 kg/m(2) with dyslipidaemia or hypertension were eligible for enrolment in this randomised, double-blind, placebo-controlled, phase 3 trial undertaken at 34 sites in the USA. Participants were prescribed mild hypocaloric diet and exercise and were randomly assigned in a 1:1:1 ratio to receive sustained-release naltrexone 32 mg per day plus sustained-release bupropion 360 mg per day combined in fixed-dose tablets (also known as NB32), sustained-release naltrexone 16 mg per day plus sustained-release bupropion 360 mg per day combined in fixed-dose tablets (also known as NB16), or matching placebo twice a day, given orally for 56 weeks. The trial included a 3-week dose escalation. Randomisation was done by use of a centralised, computer-generated, web-based system and was stratified by study centre. Co-primary efficacy endpoints at 56 weeks were percentage change in bodyweight and proportion of participants who achieved a decrease in bodyweight of 5\% or more. The primary analysis included all randomised participants with a baseline weight measurement and a post-baseline weight measurement while on study drug (last observation carried forward). This study is registered with ClinicalTrials.gov, number NCT00532779. FINDINGS: 1742 participants were enrolled and randomised to double-blind treatment (naltrexone 32 mg plus bupropion, n=583; naltrexone 16 mg plus bupropion, n=578; placebo, n=581). 870 (50\%) participants completed 56 weeks of treatment (n=296; n=284; n=290, respectively) and 1453 (83\%) were included in the primary analysis (n=471; n=471; n=511). Mean change in bodyweight was -1.3\% (SE 0.3) in the placebo group, -6.1\% (0.3) in the naltrexone 32 mg plus bupropion group (p<0.0001 vs placebo) and -5.0\% (0.3) in the naltrexone 16 mg plus bupropion group (p<0.0001 vs placebo). 84 (16\%) participants assigned to placebo had a decrease in bodyweight of 5\% or more compared with 226 (48\%) assigned to naltrexone 32 mg plus bupropion (p<0.0001 vs placebo) and 186 (39\%) assigned to naltrexone 16 mg plus bupropion (p<0.0001 vs placebo). The most frequent adverse event in participants assigned to combination treatment was nausea (naltrexone 32 mg plus bupropion, 171 participants [29.8\%]; naltrexone 16 mg plus bupropion, 155 [27.2\%]; placebo, 30 [5.3\%]). Headache, constipation, dizziness, vomiting, and dry mouth were also more frequent in the naltrexone plus bupropion groups than in the placebo group. A transient increase of around 1.5 mm Hg in mean systolic and diastolic blood pressure was followed by a reduction of around 1 mm Hg below baseline in the naltrexone plus bupropion groups. Combination treatment was not associated with increased depression or suicidality events compared with placebo. INTERPRETATION: A sustained-release combination of naltrexone plus bupropion could be a useful therapeutic option for treatment of obesity. FUNDING: Orexigen Therapeutics. Copyright 2010 Elsevier Ltd. All rights reserved.
This article was published in Lancet
and referenced in Journal of Obesity & Weight Loss Therapy